Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine
about
High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptaseIdentification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidineResistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptaseNovel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell cultureInhibition of human immunodeficiency virus type 1 reverse transcriptase by the 5'-triphosphate beta enantiomers of cytidine analogsCharacterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosidesThe M539V polymerase variant of human hepatitis B virus demonstrates resistance to 2'-deoxy-3'-thiacytidine and a reduced ability to synthesize viral DNAThe same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidineCombination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89Inhibition of duck hepatitis B virus replication by 2',3'-dideoxy-3'-fluoroguanosine in vitro and in vivoDevelopment of a new cartridge radioimmunoassay for determination of intracellular levels of lamivudine triphosphate in the peripheral blood mononuclear cells of human immunodeficiency virus-infected patientsMultiple-drug-resistant mutants of feline immunodeficiency virus selected with 2',3'-dideoxyinosine alone and in combination with 3'-azido-3'-deoxythymidineA novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (-)-beta-2',3'-dideoxy-3'-thiacytidine and 3'-azido-3'-deoxythymidineTribute to Mark WainbergThe influence of 3TC resistance mutation M184I on the fidelity and error specificity of human immunodeficiency virus type 1 reverse transcriptase.Selection and characterization of a mutant of feline immunodeficiency virus resistant to 2',3'-dideoxycytidineGeneration of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(--)-beta-L-2', 3'-dideoxy-3'-thiacytidine] in vitroMutants of feline immunodeficiency virus resistant to 2',3'-dideoxy-2',3'-didehydrothymidine.A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosidesNucleoside and nucleotide analogs select in culture for different patterns of drug resistance in human immunodeficiency virus types 1 and 2.Impaired rescue of chain-terminated DNA synthesis associated with the L74V mutation in human immunodeficiency virus type 1 reverse transcriptase.The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations.
P2860
Q28367493-5ECE8B32-1891-49C0-86FD-E51895C35C80Q28367543-F2B2F177-F58B-4068-8B65-390389789459Q28367547-0F7CF94C-1D3A-4CC2-A9B1-9FCBD9F6F5D5Q28367594-7AC86746-14A9-4857-ADA0-4EA14CA2B488Q28367642-43A8FC7C-BD21-48F6-951D-0254EA421843Q28368026-E3279EC3-9816-479E-B009-E14D7A752E90Q28368336-E162AE27-7F45-457C-94DD-CAB948FAA804Q28378626-1BBD9A5B-B35B-4E65-9D75-E8E17C3B7827Q28378896-C2A8521D-3ACA-4C3C-BFAD-9B3C71CFAA9FQ28379225-F3B6643D-8DC7-4089-9B56-841103526F51Q33699597-11F2B0AD-572B-4DA9-A09F-9C621A15DC24Q33753465-CAC77446-1188-4045-8F77-E681014FECB0Q33782477-EFA1327F-C87E-431D-A5F1-C3561338D9BDQ33846297-40FE60E5-FAF2-40DA-8C02-477A091EAA9BQ34668716-14C9776A-FB03-444E-91B7-FB9433A48040Q35123759-2E6C4319-4FD4-4A5A-82E1-DD575C411985Q35126374-A22189CB-9477-4F37-937E-BD07AD214E99Q35126454-F34E4862-3748-46A0-A070-4FA06B038707Q35879410-0FDEB755-7BDE-40E8-A44A-A46553D7C051Q37072022-A8A68A17-0F71-4C34-9884-635D1F113258Q40404514-CF1D5DC3-63D0-4C73-AFC3-8BAA7650C05FQ42117884-72F3BC8C-21FE-49E7-B298-7925591B587C
P2860
Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine
description
1993 nî lūn-bûn
@nan
1993 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Generation of drug-resistant v ...... 2',3'-dideoxy-3'-thiacytidine
@ast
Generation of drug-resistant v ...... 2',3'-dideoxy-3'-thiacytidine
@en
Generation of drug-resistant v ...... 2',3'-dideoxy-3'-thiacytidine
@nl
type
label
Generation of drug-resistant v ...... 2',3'-dideoxy-3'-thiacytidine
@ast
Generation of drug-resistant v ...... 2',3'-dideoxy-3'-thiacytidine
@en
Generation of drug-resistant v ...... 2',3'-dideoxy-3'-thiacytidine
@nl
prefLabel
Generation of drug-resistant v ...... 2',3'-dideoxy-3'-thiacytidine
@ast
Generation of drug-resistant v ...... 2',3'-dideoxy-3'-thiacytidine
@en
Generation of drug-resistant v ...... 2',3'-dideoxy-3'-thiacytidine
@nl
P2093
P2860
P356
P1476
Generation of drug-resistant v ...... 2',3'-dideoxy-3'-thiacytidine
@en
P2093
P2860
P356
10.1128/AAC.37.1.130
P407
P577
1993-01-01T00:00:00Z